130 related articles for article (PubMed ID: 20940397)
1. Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.
Ly LV; Sluijter M; Versluis M; Luyten GP; van Stipdonk MJ; van der Burg SH; Melief CJ; Jager MJ; van Hall T
Cancer Res; 2010 Nov; 70(21):8339-46. PubMed ID: 20940397
[TBL] [Abstract][Full Text] [Related]
2. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer.
Jorritsma A; Bins AD; Schumacher TN; Haanen JB
Cancer Res; 2008 Apr; 68(7):2455-62. PubMed ID: 18381454
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
4. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.
Appay V; Speiser DE; Rufer N; Reynard S; Barbey C; Cerottini JC; Leyvraz S; Pinilla C; Romero P
Eur J Immunol; 2006 Jul; 36(7):1805-14. PubMed ID: 16761313
[TBL] [Abstract][Full Text] [Related]
5. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
[TBL] [Abstract][Full Text] [Related]
6. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
7. Concurrent allorecognition has a limited impact on posttransplant vaccination.
Manzo T; Hess Michelini R; Basso V; Ricupito A; Chai JG; Simpson E; Bellone M; Mondino A
J Immunol; 2011 Feb; 186(3):1361-8. PubMed ID: 21209285
[TBL] [Abstract][Full Text] [Related]
8. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
9. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy.
Mueller K; Schweier O; Pircher H
Eur J Immunol; 2008 Oct; 38(10):2874-85. PubMed ID: 18825743
[TBL] [Abstract][Full Text] [Related]
11. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
Ma J; Wang YL; Hu HM; Fox BA; Si LS
Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
[TBL] [Abstract][Full Text] [Related]
12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
14. Development of antitumor immune responses in reconstituted lymphopenic hosts.
Hu HM; Poehlein CH; Urba WJ; Fox BA
Cancer Res; 2002 Jul; 62(14):3914-9. PubMed ID: 12124318
[TBL] [Abstract][Full Text] [Related]
15. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution.
Ma J; Urba WJ; Si L; Wang Y; Fox BA; Hu HM
Eur J Immunol; 2003 Aug; 33(8):2123-32. PubMed ID: 12884286
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration.
Eggert AA; Schreurs MW; Boerman OC; Oyen WJ; de Boer AJ; Punt CJ; Figdor CG; Adema GJ
Cancer Res; 1999 Jul; 59(14):3340-5. PubMed ID: 10416590
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.
Rossi GR; Mautino MR; Unfer RC; Seregina TM; Vahanian N; Link CJ
Cancer Res; 2005 Nov; 65(22):10555-61. PubMed ID: 16288048
[TBL] [Abstract][Full Text] [Related]
19. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
20. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
